Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | BAD | Q92934 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227273 | 0.84 | RAB9A (0.42) | LMNAPOLBTP53USP2CYP1A2 | |
| SCHEMBL4927936 | 0.84 | MKNK1 (0.44) | LMNATP53USP2CYP1A2CYP2C9 | |
| SCHEMBL3212059 | 0.83 | TSHR (0.41) | LMNAPOLBATMTP53USP2 | |
| SCHEMBL25254317 | 0.80 | SMN1; SMN2 (0.62) | LMNACASP3SENP8HPGDRAB9A | |
| SCHEMBL851750 | 0.79 | NPC1 (0.52) | LMNATP53USP2CYP1A2CYP2C9 | |
| SCHEMBL2644715 | 0.79 | SMN1; SMN2 (0.46) | LMNATP53USP2CYP1A2CYP2C9 | |
| SCHEMBL7709183 | 0.79 | LMNA (0.63) | LMNAPOLBATMTP53USP2 | |
| SCHEMBL344042 | 0.79 | RAB9A (0.53) | ATMCYP1A2HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3601696 | 0.78 | TRPM8 (0.41) | LMNAPOLBATMHPGDHCAR3 | |
| SCHEMBL13841588 | 0.77 | NPC1 (0.54) | LMNAPOLBUSP2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | disclosed |
| EP-2731932-B1 | AMINOMETHYL QUINOLONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-12-30 | — | — | EP | disclosed |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2015-08-06 | — | — | US | disclosed |
| EP-2731932-A1 | AMINOMETHYL QUINOLONE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| CN-103649053-A | Aminomethyl quinolone compounds | HOFFMANN LA ROCHE | 2014-03-19 | — | — | CN | disclosed |
| US-8501732-B2 | Aminomethyl quinolone compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013007676-A1 | AMINOMETHYL QUINOLONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-20130018043-A1 | AMINOMETHYL QUINOLONE COMPOUNDS | BILOTTA JOSEPH A (US) | 2013-01-17 | — | — | US | disclosed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018043-A1 | AMINOMETHYL QUINOLONE COMPOUNDS | MAP3K1, MAP3K11, MAP3K5 | LMNA 2209/4885POLB 2783/4885ATM 167/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885POLB 4513/4885ATM 4760/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885POLB 4513/4885ATM 4760/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885POLB 4513/4885ATM 4760/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | LMNA 2715/4885POLB 3263/4885ATM 3770/4885 |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | LMNA 2153/4885POLB 4513/4885ATM 4760/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | LMNA 1281/4885POLB 849/4885ATM 1930/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | LMNA 4690/4885POLB 2329/4885ATM 2243/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | LMNA 3454/4885POLB 3210/4885ATM 4563/4885 |
| US-20150218160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | LMNA 4465/4885POLB 3118/4885ATM 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.